Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Viking Therapeutics, Inc. (VKTX) closed at $29.73 in the latest trading session, marking a +0.61% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.91% for the day.

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...

Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity.

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

William Blair believes investors could view Viking Therapeutics (VKTX)’ multi-year manufacturing pact with CordenPharma as a negative to ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...